Site Map

  CEL-SCI Home Page  
  o About CEL-SCI  
  o History  
  o Mission and Values  
  o Business Strategy  
  o Corporate Overview  
  o Shareholder Rights Agreement  
  o Privacy Policy  
  o Corporate Headquarters  
  o Company Code of Ethics  
  o Management Team  
  o Products  
  o Cancer-Investigational Therapy Multikine  
  o Introduction to Cancer Immunotherapy  
  o Types of Biological Cancer Immunotherapy  
  Passive Immunotherapy  
  Active Immunotherapy  
  Investigational Combination Immunotherapy  
  o Limitations of Current Immunotherapies  
  o What is Investigational Multikine Therapy?  
  Introduction to Investigational Therapy Multikine
(Leukocyte Interleukin, Injection)
  Multikine is a potential combination immunotherapy:
A new class of immunotherapy drugs
  Clinical Trial Status Of Investigational Therapy Multikine (Leukocyte Interleukin, Injection)  
  Multikine Phase III Clinical Trial Design  
  Multikine Mechanism of Action  
  Potential Relevance of The Investigational Therapy Multikine (Leukocyte Interleukin, Injection) to the Medical Community Responsible for Head and Neck Cancer Patients with Advanced Disease if Approved for Marketing by the FDA  
  Head and Neck Cancer  
  Cigarette Smoking and Cancer: Q&A  
  o Infectious Diseases-L.E.A.P.S.(TM)  
  o Introduction and Overview  
  o Summary of L.E.A.P.S.(TM) and CEL-1000 Collaborators  
  o L.E.A.P.S.(TM) Scientific Backgrounder  
  o Background on CEL-1000  
  o Partnering Philosophy & Corporate Partners


  o Research & Clinical Trials  
  o Investor Relations  
  o SEC Filings  
  o Stock Quotes  
  o Scientific Publications/Presentations  
  o News & Announcements  
  o Press Releases  
  o Sign Up for News  
  o Careers  
  o Job Postings  
  o For Physicians
  o For Patients